戻る Agenda
Molecular Imaging: Utilizing It as an Effective Drug Development Tool
Session Chair(s)
Todd E. Peterson, PHD
Director, Nuclear Imaging; Associate Prof., Radiology and Radiological Sciences
Vanderbilt University, United States
Molecular imaging (MI) can assist in the development of new drugs. It can provide MI biomarkers that can be utilized in trials as endpoints for clinical outcomes. In this session, we will discuss the development of MI biomarkers and their use in drug development.
Learning Objective : Explain the benefits of PET imaging in preclinical and clinical therapeutic drug development; Recognize applications for molecular imaging in drug development phases; Identify benefits and challenges in molecular imaging from probe development to standardization in multicenter trials.
Speaker(s)
Development of Molecular Imaging Probes
Jonathan McConathy, MD, PHD
Washington University, United States
Assistant Professor of Radiology, Department of Radiology
In Vivo Preclinical Molecular Imaging in Therapeutic Drug Development
Todd E. Peterson, PHD
Vanderbilt University, United States
Director, Nuclear Imaging; Associate Prof., Radiology and Radiological Sciences
Design and Implementation of Molecular Imaging Endpoints in Multicenter Therapeutic Drug Trials
Jeffrey T. Yap, PHD
Dana-Farber Cancer Institute, United States
Senior Diagnostic Physicist